Diagnosis: Severe Alcoholic Hepatitis with Underlying Cirrhosis
This patient has severe alcoholic hepatitis (AH) with probable underlying cirrhosis, requiring immediate alcohol cessation, aggressive nutritional support, and consideration for corticosteroid therapy based on severity scoring.
Clinical Assessment
Your patient presents with classic features of alcoholic liver disease 1:
- AST/ALT ratio of 3.3 (72/21.7) - strongly suggestive of alcoholic hepatitis (ratio typically >1.5-2.0 in AH)
- Severe thrombocytopenia (40,000/µL) - indicates portal hypertension and likely underlying cirrhosis
- Hyperbilirubinemia (12.54 mg/dL total) with mixed pattern (direct 6.09, indirect 6.45)
- Hypoalbuminemia (2.33 g/dL) - reflects synthetic dysfunction
- Anemia (Hb 10.3) and elevated monocytes (1850) - common in AH
- Cholestatic pattern (elevated alkaline phosphatase 300, though GGT relatively low at 30.7)
The combination of anemia, thrombocytopenia, and hypoalbuminemia with portal hypertension features suggests this is alcoholic hepatitis superimposed on cirrhosis 1.
Severity Stratification (Critical Step)
Calculate the Modified Maddrey Discriminant Function (mDF) score immediately 1, 2:
You need the prothrombin time (PT) to calculate mDF = 4.6 × (patient PT - control PT) + serum bilirubin (mg/dL)
Also calculate MELD score 1, 3:
- MELD = 3.78×ln[bilirubin(mg/dL)] + 11.2×ln[INR] + 9.57×ln[creatinine(mg/dL)] + 6.43
With bilirubin 12.54 and creatinine 0.67, you need the INR to complete this calculation.
Severity Thresholds:
- mDF ≥32 = severe AH with 28-day mortality 30-50% without treatment 1
- MELD >20-21 = high 90-day mortality 1, 3
- Glasgow score ≥9 = high 28-day mortality 1
Immediate Management Algorithm
Step 1: Exclude Contraindications to Specific Therapy 4, 2, 5
Screen for:
- Active gastrointestinal bleeding
- Active uncontrolled infection (check blood cultures, urinalysis, diagnostic paracentesis if ascites present)
- Acute pancreatitis
- Acute kidney injury/hepatorenal syndrome
- Other causes: viral hepatitis (HBV, HCV), drug-induced liver injury, autoimmune hepatitis
Critical pitfall: Up to 20% of patients with suspected AH have alternative or additional diagnoses 1. However, given the classic AST/ALT ratio >2 and history, AH is most likely.
Step 2: Universal Interventions (All Patients) 4, 1, 4, 3
Alcohol Abstinence (Class I, Level B):
- Complete and immediate cessation 4, 3
- Assess for withdrawal risk - provide benzodiazepines if needed
- Addiction medicine consultation during hospitalization
Aggressive Nutritional Support (Class I, Level B):
- Target: 1.2-1.5 g/kg/day protein and 35-40 kcal/kg/day 1
- If critically ill: 1.5 g/kg/day protein and 40 kcal/kg/day 1
- Enteral nutrition preferred (oral supplements or nasogastric if unable to take orally) 4
- Multiple small meals (6 meals/day including late evening snack) 1
- Daily caloric intake <21.5 kcal/kg/day associated with 65.8% mortality vs 33.1% with adequate intake 3
Vitamin and Mineral Supplementation (Class B1):
- Thiamine (vitamin B1) - critical to prevent Wernicke's encephalopathy
- Folic acid
- Vitamin B12
- Pyridoxine (B6)
- Vitamin A, D
- Zinc supplementation (therapeutic doses) - improves gut barrier integrity 3
- Multivitamin daily 1
Step 3: Specific Medical Therapy Based on Severity
If mDF ≥32 or MELD >20 (Severe Disease):
First-Line: Prednisolone 40 mg/day for 28 days (Class I, Level A) 1, 4, 6, 3, 5
- Improves 28-day survival (84.6% vs 65.1% placebo, p=0.001) 1
- Use prednisolone (not prednisone - better bioavailability in liver disease)
- Alternative: Methylprednisolone 32 mg/day 6
- Contraindications: active GI bleeding, uncontrolled infection, renal failure, pancreatitis 1, 4
Assess Response at Day 7 - Calculate Lille Score 6, 5:
- Lille score ≥0.45 = non-responder → discontinue steroids 6
- Lille score <0.45 = responder → continue full 28-day course
Consider Adding N-Acetylcysteine (NAC) 6:
- NAC + corticosteroids showed 1-month and 3-month survival benefit in one trial
- Dose: Standard NAC protocol
- Weak recommendation (G2+) - not yet standard but reasonable to consider 6
If Contraindications to Steroids:
Pentoxifylline is NO LONGER RECOMMENDED 6:
- Previously suggested at 400 mg TID for 4 weeks 4
- Recent evidence shows ineffectiveness - French guidelines 2022 state "must no longer be offered" (G1-) 6
- Focus on supportive care and nutritional therapy instead
If mDF <32 and MELD <20 (Mild-Moderate Disease):
Supportive Care Only (Class III, Level A) 4:
- Nutritional support and abstinence
- Close monitoring
- No benefit from corticosteroids or other specific medical interventions 4
Additional Critical Management Points
Monitor for Complications:
Acute Kidney Injury/Hepatorenal Syndrome:
- Severe thrombocytopenia and SIRS increase AKI risk 3
- Avoid nephrotoxins: NSAIDs, aminoglycosides, IV contrast 3
- Cautious diuretic use
- Early albumin + vasoconstrictors if HRS develops 3
Infection Surveillance:
- 12-26% have infection at admission, up to 50% develop infection on steroids 3
- If on steroids: extensive bacteriological workup for any fever or clinical deterioration 6
- Consider diagnostic paracentesis if ascites present (rule out spontaneous bacterial peritonitis)
Severe Thrombocytopenia (40,000/µL):
- Bleeding risk - avoid invasive procedures unless essential
- If liver biopsy needed: transjugular route only (reduces bleeding risk) 1, 5
- Platelet transfusion only for active bleeding or pre-procedure
Role of Liver Biopsy:
Consider biopsy (transjugular route) if: 1, 5
- Diagnostic uncertainty (atypical features)
- Need to confirm diagnosis before corticosteroid therapy in severe cases
- Prognostic information needed
Not routinely required - diagnosis can be made clinically with typical presentation 1, 2, 5
Prognosis and Follow-up
Short-term (3 months):
- Mortality primarily related to severity of hepatitis and liver function improvement 6
- Alcohol resumption has minimal impact on 3-month mortality 6
Long-term (beyond 3 months):
- Abstinence is the dominant factor for survival 6, 3
- 5-year survival: 80% with abstinence vs 50% with relapse 6
- Addiction treatment must be systematically offered after AH episode 6
Common Pitfall: The relatively low GGT (30.7) is unusual but can occur in severe AH with cholestasis 7. The elevated direct bilirubin (6.09) and alkaline phosphatase suggest a cholestatic component, which is associated with worse prognosis 1, 8. This does not change management but reinforces the need for aggressive treatment.